RECURSION PHARMACEUTICALS, INC. (RXRX)

3.34 -2.91% (-0.10)

Over 3Y: -61.0%

2026-08-28
Style
Area Line Line with markersneeds a shorter window Steps Candlesneeds a shorter window Hollow candlesneeds a shorter window Barsneeds a shorter window

Candles need the day’s open, high and low. Those are being collected now — a company shows them once its history has been refreshed.

5 10 15
2023 2024 2025 2026

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '21 — Revenue: 2.5M Q3 '21 — Operating Cash Flow: -33M Q3 '21 — Free Cash Flow: -42.8M Q3 '21 — Net Income: -47.4M Q4 '21 — Revenue: 2.5M Q4 '21 — Operating Cash Flow: -61.2M Q4 '21 — Free Cash Flow: -65.6M Q4 '21 — Net Income: -64.9M Q1 '22 — Revenue: 5.3M Q1 '22 — Operating Cash Flow: 77.4M Q1 '22 — Free Cash Flow: 73M Q1 '22 — Net Income: -56M Q2 '22 — Revenue: 7.7M Q2 '22 — Operating Cash Flow: -61.6M Q2 '22 — Free Cash Flow: -78.1M Q2 '22 — Net Income: -65.6M Q3 '22 — Revenue: 13.2M Q3 '22 — Operating Cash Flow: -54.5M Q3 '22 — Free Cash Flow: -62.8M Q3 '22 — Net Income: -60.4M Q4 '22 — Revenue: 13.7M Q4 '22 — Operating Cash Flow: -44.7M Q4 '22 — Free Cash Flow: -52.7M Q4 '22 — Net Income: -57.5M Q1 '23 — Revenue: 12.1M Q1 '23 — Operating Cash Flow: -73.3M Q1 '23 — Free Cash Flow: -78.5M Q1 '23 — Net Income: -65.3M Q2 '23 — Revenue: 11M Q2 '23 — Operating Cash Flow: -67.5M Q2 '23 — Free Cash Flow: -71.4M Q2 '23 — Net Income: -76.7M Q3 '23 — Revenue: 10.5M Q3 '23 — Operating Cash Flow: -72.9M Q3 '23 — Free Cash Flow: -73.7M Q3 '23 — Net Income: -93M Q4 '23 — Revenue: 10.9M Q4 '23 — Operating Cash Flow: -74.1M Q4 '23 — Free Cash Flow: -76.1M Q4 '23 — Net Income: -93M Q1 '24 — Revenue: 13.8M Q1 '24 — Operating Cash Flow: -102.3M Q1 '24 — Free Cash Flow: -109M Q1 '24 — Net Income: -91.4M Q2 '24 — Revenue: 14.4M Q2 '24 — Operating Cash Flow: -82.2M Q2 '24 — Free Cash Flow: -83.4M Q2 '24 — Net Income: -97.5M Q3 '24 — Revenue: 26.1M Q3 '24 — Operating Cash Flow: -59.2M Q3 '24 — Free Cash Flow: -63.8M Q3 '24 — Net Income: -95.8M Q4 '24 — Revenue: 4.5M Q4 '24 — Operating Cash Flow: -115.4M Q4 '24 — Free Cash Flow: -116.7M Q4 '24 — Net Income: -178.9M Q1 '25 — Revenue: 14.7M Q1 '25 — Operating Cash Flow: -132M Q1 '25 — Free Cash Flow: -133.8M Q1 '25 — Net Income: -202.5M Q2 '25 — Revenue: 19.2M Q2 '25 — Operating Cash Flow: -76.4M Q2 '25 — Free Cash Flow: -79.6M Q2 '25 — Net Income: -171.9M Q3 '25 — Revenue: 5.2M Q3 '25 — Operating Cash Flow: -117.4M Q3 '25 — Free Cash Flow: -117.6M Q3 '25 — Net Income: -162.3M Q4 '25 — Revenue: 35.5M Q4 '25 — Operating Cash Flow: -46.1M Q4 '25 — Free Cash Flow: -47.3M Q4 '25 — Net Income: -108.1M Q1 '26 — Revenue: 6.5M Q1 '26 — Operating Cash Flow: -81.1M Q1 '26 — Free Cash Flow: -81.4M Q1 '26 — Net Income: -117.5M Q2 '26 — Revenue: 7.7M Q2 '26 — Operating Cash Flow: -105.9M Q2 '26 — Free Cash Flow: -106M Q2 '26 — Net Income: -131M -180M -120M -60M 0 60M 120M
Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.6
SBC / sales 165.4%
OE margin -807.6%
Oper. margin -991.7%
ROIC -112.1%
Accruals -13.9%
Asset turnover 0.045×
EBITDA margin -848.9%
FCF margin -642.2%
OCF margin -638.9%
Profit margin -945.9%
ROA -42.8%
ROCE -49.8%
ROE -56.7%
OCF / EBIT —

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

6.0
RPO / sales 0.5×
RPO growth —
Segment HHI —

4 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

6.5
ND/EBITDA —
Interest cover -367.3×
Cash / Debt 38.4×
Debt / Eq 0.016×
Debt payback 0.0 yr
Quick ratio 5.0×
Cash runway 1.5 yr
F-score 4.0 pts
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

4.8
Sales CAGR 4Y +64.6%
Sales/sh Y/Y -48.0%
Sales Q/Q -60.1%
Shares change +63.2%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.